Enanta Pharmaceuticals files to sell up to $75M of common stock in at-the-market offering

Filed July 2, 2026 · ~1 min read

Key Changes

• high

  Enanta may sell up to $75.0 million of common stock from time to time in an at-the-market offering, with shares priced at prevailing market prices.

  The Offering verify on EDGAR →
• high

  The offering is primary only; all net proceeds go to Enanta for clinical trials, R&D, working capital, and general corporate purposes.

  Use of Proceeds verify on EDGAR →
• high

  Based on an assumed offering price of $14.77 per share, new investors would experience immediate dilution of $9.23 per share.

  Dilution verify on EDGAR →